Figure 7
RNAi by Nanobody-R9MTG–siRNA. (a) Western blot analysis of GAPDH in the A431 cell extract mixed with Nanobody-R9MTG–siRNA using anti-GAPDH monoclonal antibody. (b) Real time PCR of the transcript in A431 cell extract mixed with Nanobody-R9MTG–siRNA. Lipofectamine was used as a positive control. PBS phosphate buffered saline, Lipo lipofectamine, 6 and 30 indicate the Nanobody-R9MTG/siRNA ratio. T-test showed less than 0.05 for all combinations except between PBS and siRNA (T-test < 0.54). Full-length gel image for (a) provided in Supplementary Fig. S7.
